Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice.

Polson ES, Kuchler VB, Abbosh C, Ross EM, Mathew RK, Beard HA, da Silva B, Holding AN, Ballereau S, Chuntharpursat-Bon E, Williams J, Griffiths HBS, Shao H, Patel A, Davies AJ, Droop A, Chumas P, Short SC, Lorger M, Gestwicki JE, Roberts LD, Bon RS, Allison SJ, Zhu S, Markowetz F, Wurdak H.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaar2718. doi: 10.1126/scitranslmed.aar2718.

2.

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.

Fulton B, Short SC, James A, Nowicki S, McBain C, Jefferies S, Kelly C, Stobo J, Morris A, Williamson A, Chalmers AJ.

Clin Transl Radiat Oncol. 2017 Nov 21;8:12-16. doi: 10.1016/j.ctro.2017.11.003. eCollection 2018 Jan.

3.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

4.

Systematic Review of Synthetic Computed Tomography Generation Methodologies for Use in Magnetic Resonance Imaging-Only Radiation Therapy.

Johnstone E, Wyatt JJ, Henry AM, Short SC, Sebag-Montefiore D, Murray L, Kelly CG, McCallum HM, Speight R.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):199-217. doi: 10.1016/j.ijrobp.2017.08.043. Epub 2017 Sep 8. Review.

5.

Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.

Levesley J, Steele L, Brüning-Richardson A, Davison A, Zhou J, Ding C, Lawler S, Short SC.

Neuro Oncol. 2018 Jan 22;20(2):203-214. doi: 10.1093/neuonc/nox134.

6.

RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells.

King HO, Brend T, Payne HL, Wright A, Ward TA, Patel K, Egnuni T, Stead LF, Patel A, Wurdak H, Short SC.

Stem Cell Reports. 2017 Jan 10;8(1):125-139. doi: 10.1016/j.stemcr.2016.12.005.

7.

Development of clinical simultaneous SPECT/MRI.

Hutton BF, Occhipinti M, Kuehne A, Máthé D, Kovács N, Waiczies H, Erlandsson K, Salvado D, Carminati M, Montagnani GL, Short SC, Ottobrini L, van Mullekom P, Piemonte C, Bukki T, Nyitrai Z, Papp Z, Nagy K, Niendorf T, de Francesco I, Fiorini C; INSERT consortium.

Br J Radiol. 2018 Jan;91(1081):20160690. doi: 10.1259/bjr.20160690. Epub 2017 Mar 7.

8.

Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).

Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Götz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu AL.

BMC Cancer. 2016 Oct 5;16(1):769.

9.

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.

Hayes J, Thygesen H, Gregory W, Westhead DR, French PJ, Van Den Bent MJ, Lawler SE, Short SC.

Mol Oncol. 2016 Oct;10(8):1296-304. doi: 10.1016/j.molonc.2016.06.004. Epub 2016 Jul 1.

10.

Science in Focus: MicroRNA in Glioma - Potential as Biomarkers and Therapeutic Targets.

Short SC.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):543-6. doi: 10.1016/j.clon.2016.04.048. Epub 2016 May 13. No abstract available.

PMID:
27184942
11.

NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.

Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M.

Oncotarget. 2016 Jul 5;7(27):41251-41264. doi: 10.18632/oncotarget.9275.

12.

ESTRO-ACROP guideline "target delineation of glioblastomas".

Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, Grosu AL, Lagerwaard FJ, Minniti G, Mirimanoff RO, Ricardi U, Short SC, Weber DC, Belka C.

Radiother Oncol. 2016 Jan;118(1):35-42. doi: 10.1016/j.radonc.2015.12.003. Epub 2016 Jan 6.

PMID:
26777122
13.

Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours.

Kyriakakis N, Lynch J, Orme SM, Gerrard G, Hatfield P, Loughrey C, Short SC, Murray RD.

Clin Endocrinol (Oxf). 2016 Mar;84(3):372-9. doi: 10.1111/cen.12969. Epub 2015 Nov 24.

PMID:
26501843
14.

Prognostic microRNAs in high-grade glioma reveal a link to oligodendrocyte precursor differentiation.

Hayes J, Thygesen H, Droop A, Hughes TA, Westhead D, Lawler SE, Wurdak H, Short SC.

Oncoscience. 2014 Dec 26;2(3):252-62. eCollection 2015.

15.

Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.

Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, Westhead D, Alder JE, Shaw L, Short SC, Lawler SE.

Mol Oncol. 2015 Mar;9(3):704-14. doi: 10.1016/j.molonc.2014.11.004. Epub 2014 Nov 28.

16.

Benchmarking of a treatment planning system for spot scanning proton therapy: comparison and analysis of robustness to setup errors of photon IMRT and proton SFUD treatment plans of base of skull meningioma.

Harding R, Trnková P, Weston SJ, Lilley J, Thompson CM, Short SC, Loughrey C, Cosgrove VP, Lomax AJ, Thwaites DI.

Med Phys. 2014 Nov;41(11):111710. doi: 10.1118/1.4897571.

PMID:
25370624
17.

Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer.

Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ, Short SC, Freeman A, Powles T, Hoskin PJ, West CM, Kelly JD.

Int J Cancer. 2015 Feb 1;136(3):709-20. doi: 10.1002/ijc.29022. Epub 2014 Jul 22.

18.

Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy.

Westbury CB, Haviland J, Davies S, Gothard L, Abdi BA, Sydenham M, Bowen J, Stratton R, Short SC, Yarnold JR.

Radiat Oncol. 2014 Apr 30;9:103. doi: 10.1186/1748-717X-9-103.

19.

Changes in mast cell number and stem cell factor expression in human skin after radiotherapy for breast cancer.

Westbury CB, Freeman A, Rashid M, Pearson A, Yarnold JR, Short SC.

Radiother Oncol. 2014 May;111(2):206-11. doi: 10.1016/j.radonc.2014.02.020. Epub 2014 Apr 17.

PMID:
24746564
20.

Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.

Rankeillor KL, Cairns DA, Loughrey C, Short SC, Chumas P, Ismail A, Chakrabarty A, Lawler SE, Roberts P.

J Neurooncol. 2014 Apr;117(2):243-51. doi: 10.1007/s11060-014-1372-y. Epub 2014 Feb 20.

PMID:
24554053
21.

Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study.

Maclean J, Fersht N, Singhera M, Mulholland P, McKee O, Kitchen N, Short SC.

Radiat Oncol. 2013 Jun 27;8:156. doi: 10.1186/1748-717X-8-156.

22.

Sequential transformation of mesenchymal stem cells is associated with increased radiosensitivity and reduced DNA repair capacity.

Worku M, Fersht N, Martindale C, Funes JM, Short SC.

Radiat Res. 2013 Jun;179(6):698-706. doi: 10.1667/RR2998.1. Epub 2013 May 6.

PMID:
23647005
23.

The role of autophagy in clinical practice.

Swampillai AL, Salomoni P, Short SC.

Clin Oncol (R Coll Radiol). 2012 Aug;24(6):387-95. doi: 10.1016/j.clon.2011.09.010. Epub 2011 Oct 26. Review.

PMID:
22032864
24.

Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.

Short SC, Giampieri S, Worku M, Alcaide-German M, Sioftanos G, Bourne S, Lio KI, Shaked-Rabi M, Martindale C.

Neuro Oncol. 2011 May;13(5):487-99. doi: 10.1093/neuonc/nor010. Epub 2011 Mar 1.

25.

BRCA1 and BRCA2 heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity.

Sioftanos G, Ismail A, Föhse L, Shanley S, Worku M, Short SC.

Int J Radiat Biol. 2010 Dec;86(12):1095-105. doi: 10.3109/09553002.2010.501836. Epub 2010 Oct 28.

PMID:
20979543
26.

Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.

Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1511-9. doi: 10.1016/j.ijrobp.2009.07.1703.

PMID:
19931733
27.

Re-irradiation of brain tumours--evidence, indications and limitations.

Short SC.

Eur J Cancer. 2009 Sep;45 Suppl 1:410-1. doi: 10.1016/S0959-8049(09)70068-1. No abstract available.

PMID:
19775650
28.

Management of glioblastoma multiforme in HIV patients: a case series and review of published studies.

Hall JR, Short SC.

Clin Oncol (R Coll Radiol). 2009 Oct;21(8):591-7. doi: 10.1016/j.clon.2009.04.006. Epub 2009 Jul 8. Review.

PMID:
19589665
29.

Survival from brain tumours in England and Wales up to 2001.

Short SC.

Br J Cancer. 2008 Sep 23;99 Suppl 1:S102-3. doi: 10.1038/sj.bjc.6604604. No abstract available.

30.

DNA repair after irradiation in glioma cells and normal human astrocytes.

Short SC, Martindale C, Bourne S, Brand G, Woodcock M, Johnston P.

Neuro Oncol. 2007 Oct;9(4):404-11. Epub 2007 Aug 17.

31.

Dose- and time-dependent changes in gene expression in human glioma cells after low radiation doses.

Short SC, Buffa FM, Bourne S, Koritzinsky M, Wouters BG, Bentzen SM.

Radiat Res. 2007 Aug;168(2):199-208.

PMID:
17638411
32.

ATR-dependent radiation-induced gamma H2AX foci in bystander primary human astrocytes and glioma cells.

Burdak-Rothkamm S, Short SC, Folkard M, Rothkamm K, Prise KM.

Oncogene. 2007 Feb 15;26(7):993-1002. Epub 2006 Aug 7.

PMID:
16909103
33.

Diffuse pigmented villonodular synovitis of the foot and ankle treated with surgery and radiotherapy.

Lee M, Mahroof S, Pringle J, Short SC, Briggs TW, Cannon SR.

Int Orthop. 2005 Dec;29(6):403-5.

34.

Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo.

Krause M, Wohlfarth J, Georgi B, Pimentel N, Dorner D, Zips D, Eicheler W, Hessel F, Short SC, Joiner MC, Baumann M.

Int J Radiat Biol. 2005 Oct;81(10):751-8.

PMID:
16449082
35.

DNA damage responses at low radiation doses.

Short SC, Bourne S, Martindale C, Woodcock M, Jackson SP.

Radiat Res. 2005 Sep;164(3):292-302.

PMID:
16137202
36.

A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer.

Short SC, Suovuori A, Cook G, Vivian G, Harmer C.

Clin Oncol (R Coll Radiol). 2004 Dec;16(8):569-74.

PMID:
15630851
37.

Low dose hyper-radiosensitivity in metastatic tumors.

Harney J, Short SC, Shah N, Joiner M, Saunders MI.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1190-5.

PMID:
15234055
38.

Primary central nervous system lymphoma with testicular relapse.

Harney J, Pope A, Short SC.

Clin Oncol (R Coll Radiol). 2004 May;16(3):193-5.

PMID:
15191006
39.

Radiobiology and vascular targeting in glioma.

Short SC, Harney J.

Curr Opin Neurol. 2003 Dec;16(6):651-5. Review.

PMID:
14624072
40.

External beam and conformal radiotherapy in the management of gliomas.

Short SC.

Acta Neurochir Suppl. 2003;88:37-43.

PMID:
14531559
41.

Ultrafractionation in A7 human malignant glioma in nude mice.

Krause M, Hessel F, Wohlfarth J, Zips D, Hoinkis C, Foest H, Petersen C, Short SC, Joiner MC, Baumann M.

Int J Radiat Biol. 2003 Jun;79(6):377-83.

PMID:
12963539
42.
43.

Effects of cell cycle phase on low-dose hyper-radiosensitivity.

Short SC, Woodcock M, Marples B, Joiner MC.

Int J Radiat Biol. 2003 Feb;79(2):99-105.

PMID:
12569013
44.

Temozolomide as second-line chemotherapy for relapsed gliomas.

Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, Brada M.

J Neurooncol. 2002 May;57(3):247-51.

PMID:
12125988
45.

Low-dose hypersensitivity after fractionated low-dose irradiation in vitro.

Short SC, Kelly J, Mayes CR, Woodcock M, Joiner MC.

Int J Radiat Biol. 2001 Jun;77(6):655-64.

PMID:
11403705
46.

Thalidomide as an anti-angiogenic agent in relapsed gliomas.

Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M.

J Neurooncol. 2001 Jan;51(1):41-5.

PMID:
11349879
47.

The treatment of malignant cerebral tumours.

Short SC, Brada M.

Hosp Med. 2000 Nov;61(11):772-7. Review.

PMID:
11198745
48.

Low-dose hypersensitivity: current status and possible mechanisms.

Joiner MC, Marples B, Lambin P, Short SC, Turesson I.

Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):379-89. Review.

PMID:
11173131
49.

The response of human glioma cell lines to low-dose radiation exposure.

Short SC, Mitchell SA, Boulton P, Woodcock M, Joiner MC.

Int J Radiat Biol. 1999 Nov;75(11):1341-8.

PMID:
10597908
50.

Cellular response to low-dose irradiation.

Short SC, Joiner MC.

Clin Oncol (R Coll Radiol). 1998;10(2):73-7. Review. No abstract available.

PMID:
9610894

Supplemental Content

Loading ...
Support Center